| Year |
Citation |
Score |
| 2016 |
Bolyard CM, Meisen WH, Banasavadi-Siddegowda Y, Hardcastle J, Yoo JY, Wohleb ES, Wojton J, Yu JG, Dubin S, Khosla M, Xu B, Smith JG, Alvarez-Breckenridge C, Pow-Anpongkul P, Pichiorri F, et al. BAI1 Orchestrates Macrophage Inflammatory Response to HSV Infection- implications for Oncolytic Viral Therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27852701 DOI: 10.1158/1078-0432.Ccr-16-1818 |
0.543 |
|
| 2016 |
Hardcastle J, Mills L, Malo CS, Jin F, Kurokawa C, Geekiyanage H, Schroeder M, Sarkaria J, Johnson AJ, Galanis E. Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment. Neuro-Oncology. PMID 27663389 DOI: 10.1093/Neuonc/Now179 |
0.385 |
|
| 2015 |
Meisen WH, Wohleb ES, Jaime-Ramirez AC, Bolyard C, Yoo JY, Russell L, Hardcastle J, Dubin S, Muili K, Yu J, Caligiuri M, Godbout J, Kaur B. The Impact of Macrophage- and Microglia-Secreted TNFα on Oncolytic HSV-1 Therapy in the Glioblastoma Tumor Microenvironment. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 3274-85. PMID 25829396 DOI: 10.1158/1078-0432.Ccr-14-3118 |
0.768 |
|
| 2014 |
Wojton J, Meisen WH, Jacob NK, Thorne AH, Hardcastle J, Denton N, Chu Z, Dmitrieva N, Marsh R, Van Meir EG, Kwon CH, Chakravarti A, Qi X, Kaur B. SapC-DOPS-induced lysosomal cell death synergizes with TMZ in glioblastoma. Oncotarget. 5: 9703-9. PMID 25210852 DOI: 10.18632/Oncotarget.2232 |
0.621 |
|
| 2012 |
Alvarez-Breckenridge CA, Yu J, Price R, Wojton J, Pradarelli J, Mao H, Wei M, Wang Y, He S, Hardcastle J, Fernandez SA, Kaur B, Lawler SE, Vivier E, Mandelboim O, et al. NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors. Nature Medicine. 18: 1827-34. PMID 23178246 DOI: 10.1038/Nm.3013 |
0.643 |
|
| 2011 |
Chiocca EA, Aguilar LK, Bell SD, Kaur B, Hardcastle J, Cavaliere R, McGregor J, Lo S, Ray-Chaudhuri A, Chakravarti A, Grecula J, Newton H, Harris KS, Grossman RG, Trask TW, et al. Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 3611-9. PMID 21844505 DOI: 10.1200/Jco.2011.35.5222 |
0.482 |
|
| 2010 |
Hardcastle J, Kurozumi K, Dmitrieva N, Sayers MP, Ahmad S, Waterman P, Weissleder R, Chiocca EA, Kaur B. Enhanced antitumor efficacy of vasculostatin (Vstat120) expressing oncolytic HSV-1 Molecular Therapy. 18: 285-294. PMID 19844198 DOI: 10.1038/Mt.2009.232 |
0.581 |
|
| 2008 |
Kurozumi K, Hardcastle J, Thakur R, Shroll J, Nowicki M, Otsuki A, Chiocca EA, Kaur B. Oncolytic HSV-1 infection of tumors induces angiogenesis and upregulates CYR61. Molecular Therapy : the Journal of the American Society of Gene Therapy. 16: 1382-91. PMID 18545226 DOI: 10.1038/Mt.2008.112 |
0.56 |
|
| 2007 |
Kurozumi K, Hardcastle J, Thakur R, Yang M, Christoforidis G, Fulci G, Hochberg FH, Weissleder R, Carson W, Chiocca EA, Kaur B. Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy. Journal of the National Cancer Institute. 99: 1768-81. PMID 18042934 DOI: 10.1093/Jnci/Djm229 |
0.525 |
|
| 2007 |
Hardcastle J, Kurozumi K, Chiocca EA, Kaur B. Oncolytic viruses driven by tumor-specific promoters. Current Cancer Drug Targets. 7: 181-9. PMID 17346110 DOI: 10.2174/156800907780058880 |
0.547 |
|
| Show low-probability matches. |